Dr. Lal PathLabs Independent Director Gurinder Singh Kalra steps down

Dr. Lal PathLabs Limited announced that Gurinder Singh Kalra has ceased to be an independent director of the company with effect from July 26, 2026 (closing business hours). The departure follows the completion of his current tenure as an independent director, a routine corporate governance event rather than a resignation or removal.

The company disclosed the change to the National Stock Exchange of India Limited and BSE Limited on July 26, 2026, citing Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation also referenced SEBI Circular No. SEBI/HO/CFD/CFD-POD-1/P/CIR/2023/123 dated July 13, 2023, which mandates specific disclosures regarding changes in directorship.

Vinay Gujral, Company Secretary and Compliance Officer of Dr. Lal PathLabs Limited, signed the disclosure filed with the exchanges. The filing included Annexure-A, which detailed the particulars of the cessation as required under the regulatory framework.

Key Details of Cessation

Particulars	Details
Director Name	Gurinder Singh Kalra
DIN	10197218
Reason for Change	Completion of tenure as Independent Director
Date of Cessation	July 26, 2026 (closing business hours)

The cessation is classified under "otherwise" in the regulatory filing, distinguishing it from appointments, reappointments, resignations, or removals. No brief profile or disclosure of relationships between directors was applicable for this cessation event, as noted in the annexure.

What This Means for Governance

The departure of an independent director due to tenure completion is a standard procedural step in corporate governance cycles. Companies are required to fill such vacancies through board recommendations and shareholder approvals at subsequent general meetings to maintain the required proportion of independent directors on the Board. Until a successor is appointed, the Board continues to function with the remaining directors, ensuring continuity in oversight and strategic guidance for Dr. Lal PathLabs Limited.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+4.27%	+1.53%	+5.37%	+27.81%	+16.61%	+2.22%

Dr. Lal PathLabs reported a 27.2% year-on-year increase in consolidated net profit to ₹1,705 crore for the quarter ended June 30, 2026, driven by robust volume-led revenue growth and expanding operating margins. The diagnostics company’s total income from operations rose 18.9% to ₹8,296 crore, while EBITDA grew 28.7% to ₹2,564 crore, with margins improving to 30.9% from 28.7% in the previous year. The Board of Directors approved an interim dividend of ₹5 per equity share, payable to shareholders on record by July 30, 2026.

Financial Performance

The company demonstrated strong operational efficiency, with profit before tax rising 26.3% to ₹2,287 crore. Standalone results also reflected this upward trajectory, with standalone net profit increasing 28.3% to ₹1,659 crore. The growth was underpinned by higher sample volumes rather than price hikes, indicating sustained demand across its network. Basic earnings per share (EPS) stood at ₹10.15, up from ₹7.94 in Q1FY26.

Metric	Q1FY27 (₹ Cr)	Q1FY26 (₹ Cr)	YoY Change
Total Income from Operations	8,296	6,979	18.9%
Consolidated Net Profit	1,705	1,340	27.2%
Profit Before Tax	2,287	1,811	26.3%
Basic EPS (₹)	10.15	7.94	27.8%

Operational Highlights

Revenue growth was primarily volume-driven, with sample volumes increasing by 10.7% year-on-year and patient volumes rising by 8.2%. As of March 31, 2026, Dr. Lal PathLabs operated 312 clinical laboratories, 7,727 Patient Service Centers (PSCs), and 13,935 Pick-up Points (PUPs). The company serviced over 1 lakh patients through its rural outreach program in seven states during the quarter.

Strategic Acquisitions and ESOPs

Dr. Lal PathLabs expanded its international and technological footprint through two key acquisitions approved by its subsidiaries:

Sunshine Healthcare Limited (Ghana): An 80% stake acquired for up to GHS 45.6 million (approx. ₹380 million) to strengthen presence in West Africa.
Neuome Technologies Private Limited: A 30% stake acquired for up to ₹35 million to enhance pre-analytical technology capabilities.

Additionally, the Board approved the granting of 119,300 stock options under the Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2025 to eligible employees. The exercise price is set at the face value of ₹10 per share, with vesting occurring between one and four years from the grant date.

What the Numbers Show

The disproportionate growth in net profit (27.2%) compared to revenue (18.9%) highlights significant operating leverage. Group CFO Ved Goel attributed this to "disciplined execution" and an improved test mix. The acquisition of Shahbazkers Diagnostic Centre earlier in the quarter contributed to top-line growth, while cash reserves stood at ₹1,693 crore as of June 30, 2026. The company noted that it evaluates performance as a single unit, with no reportable segments under Ind AS 108.